What Hovid Berhad does

Hovid Berhad is a Malaysian publicly listed pharmaceutical manufacturer founded in 1980 by David Ho (Ho Sue San @ David Ho Sue San) and headquartered in Ipoh, Perak, Malaysia. The company originated as a herbal tea producer under the Ho Yan Hor brand and has since transformed into a branded generics manufacturer with a portfolio of more than 400 products covering prescription medicines across cardiovascular, respiratory, central nervous system, anti-infectives, oncology, and organ transplantation (immunosuppressants such as Mofecon and Tacrocord), as well as OTC dietary supplements, medical devices, disinfectant solutions, and consumer health products. Its proprietary technology backbone is the SupraBio self-emulsifying drug delivery system, developed for enhanced absorption of lipophilic compounds such as tocotrienols, with targeted organ delivery capability. The company was the first in Malaysia and globally to extract carotenoids and tocotrienols from palm oil on a commercial scale for pharmaceutical applications, forming the basis of its TOCOVID branded supplement line, which is currently in USFDA Phase II clinical trials for orphan-disease indications.

Hovid operates a multi-channel go-to-market model combining direct field sales to hospital and pharmacy accounts in Malaysia, wholly-owned distribution subsidiaries in the Philippines (Hovid Inc.), Hong Kong (Hovid Limited), and the United Kingdom (Hovid UK), and export distribution to more than 50 countries across Southeast Asia, the Middle East, Africa, Europe, and the Americas. Export markets account for 55% of total revenue, and consumer products are also sold through D2C e-commerce channels including Lazada, Shopee (Hovid Nutriworld), and the hovidonlinestore.com storefront. Revenue streams consist of one-time sales of generic pharmaceutical products, OTC supplements, and consumer health items, plus hardware sales of medical devices such as blood glucose monitors.

The company holds regulatory certifications including TGA-GMP (Australia, 2022), NPRA compliance, and is pursuing USFDA Phase II clinical trials for its lead innovative product. It has received multiple recognitions, including Malaysia's Growth Champions 2021, the Export Excellence Awards 2021 (Silver), and EPF Top Employer 2024. Leadership remains founder/family-controlled, with David Ho as Managing Director and Chairman and Sarah Ho Lee Mun as Executive Director overseeing the group's sales and marketing globally.

Name

Hovid Berhad

Legal name

Hovid Berhad

Website

https://hovid.com

Company type

Public

Founded year

1980

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Hovid Berhad is a Malaysian publicly listed pharmaceutical manufacturer founded in 1980, producing 400+ generic drugs, OTC supplements, and consumer health products distributed across 50+ countries, anchored by its proprietary SupraBio tocotrienol delivery technology.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Healthy Aging & Cognitive Support Supplements (CRADAGAM), Herbal & Botanical Supplements (CRADAGAD)

Keywords

• Generic pharmaceutical manufacturing
• Over-the-counter supplements
• Tocotrienol health products
• Immunosuppressant medications
• Medical device manufacturing

Headquarters

HQ city

Ipoh

HQ country

Malaysia

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Products: Manufacturing and sale of branded generic pharmaceutical products including prescription medicines across therapeutic categories such as cardiovascular, respiratory, nervous system, anti-infectives, and oncology. Revenue generated through direct sales to pharmacies, hospitals, and healthcare providers.
2. Dietary Supplements & Consumer Health: Sale of OTC supplements, dietary products, and consumer health solutions including vitamins, herbal teas (Ho Yan Hor), and wellness products through pharmacy retail and direct channels.
3. Medical Devices & Disinfectants: Sale of medical devices including blood glucose monitoring devices and disinfectant solutions to healthcare facilities and consumers.
4. Export & International Distribution: Export revenue from sales to over 50 countries globally, with subsidiaries in Philippines, Hong Kong, and UK serving regional markets. Contributes 55% of total revenue.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Hovid Berhad is a Malaysian pharmaceutical manufacturer that develops, produces, and distributes over 400 branded generic pharmaceutical products, over-the-counter supplements, medical devices, disinfectant solutions, and consumer health products. Its portfolio spans cardiovascular, respiratory, CNS, anti-infective, oncology, and organ transplantation therapeutics, alongside innovative tocotrienol-based supplements under the TOCOVID brand built on its proprietary SupraBio self-emulsifying drug delivery technology. Products reach over 50 countries through direct sales, wholly-owned regional subsidiaries, and international distribution partners.

Product overview

Hovid Berhad is a Malaysian pharmaceutical company with a portfolio of over 400 pharmaceutical products, over-the-counter supplements, disinfectant solutions, medical devices, and consumer products distributed across more than 50 countries. The company operates as a branded generic pharmaceutical producer with capabilities in product research and development, manufacturing, and global distribution. The product portfolio includes innovative tocotrienol-based products under the TOCOVID brand (SupraBio supplements, Vitality drinks, D' Repair Cream), traditional herbal teas under the Ho Yan Hor brand, a comprehensive range of prescription pharmaceuticals covering anti-infectives (60 products), respiratory (37 products), nervous system (33 products), dietary supplements (32 products), cardiovascular (20 products), dermatologicals (22 products), and specialty areas including oncology, organ transplantation immunosuppressants, and medical devices. The company has made significant investments in R&D including being among the first to extract tocotrienols from palm oil and develop the proprietary SupraBio self-emulsifying drug delivery system.

Differentiator

Problem solved

Functional benefit

Brands

• Ho Yan Hor: Herbal tea brand - Hovid's first and longest-standing household brand, originally a herbal tea company before transformation to pharmaceutical.
• TOCOVID
• Hovid Nutriworld

Products and services

• Tocovid SupraBio Range Premium line of tocotrienol supplements extracted from palm oil using the proprietary SupraBio self-emulsifying system, available in 50mg, 100mg, and 200mg soft gels and Promemo formulation, targeted at consumers seeking enhanced nutrient absorption.
• Tocovid Vitality Nutritional drink formulated with tocotrienols, vitamins, minerals, proteins, and other nutrients for overall vitality and health, available in Vanilla and Yam flavors, sold through pharmacy retail and online stores.
• Tocovid D' Repair Cream Topical cream containing 15% w/w tocotrienols and tocopherols marketed for skin repair applications, sold through pharmacy retail and consumer channels.
• Ho Yan Hor Herbal Tea Range Traditional herbal tea brand and medicated oils with over 80 years of heritage and 8 herbal tea variants, sold through pharmacy, retail, and consumer channels in Malaysia and export markets.
• Hovid Mofecon (Mycophenolate) Products Mycophenolate-based immunosuppressant medications for organ transplantation, including Mofecon 250mg capsules, Mofecon 500mg tablets, and Mofecon-GR 180mg and 360mg gastro-resistant tablets, supplied to hospital and transplant centres.
• Hovid Tacrocord (Tacrolimus) Products Tacrolimus immunosuppressant capsules for organ transplantation, available in 0.5mg, 1mg, and 5mg dosages, sold to hospitals and transplant centres.
• Hovid Oncology Products Cancer treatment medications including Hovid Fulvestrant injection, Hovid Gefitinib tablets (targeted therapy), Hovid Irinotecan, Hovid Oxaliplatin, and Hovid Ondansetron antiemetic, supplied to oncology treatment centres and hospitals.
• Hovid Cardiovascular Products Cardiovascular medications including angiotensin-receptor blockers (ARBs), antiplatelets, beta blockers, calcium channel blockers, and dyslipidaemic agents across more than 20 products, dispensed through pharmacies and hospitals.
• Hovid Respiratory Products Respiratory medications including anti-asthma/COPD products, antihistamines, and cough/cold preparations across more than 37 products such as Hovid Ventamol, Hovid Ventacort, and Hovid Montelair, sold through pharmacies and hospitals.
• Hovid CNS Products Central nervous system medications including analgesics, antipyretics, anticonvulsants, antidepressants, antipsychotics, and NSAIDs (oral and topical) across more than 33 products, supplied to pharmacies, hospitals, and clinics.
• Hovid Anti-Infectives Anti-infective medications including antibacterials (49 products), antifungals (4), antiprotozoals (3), and antivirals (4), totalling more than 60 products, distributed through pharmacies and hospitals.
• Hovid Dietary Supplements Range of dietary supplements covering anemia, antioxidants, bone health, brain health, digestive health, heart health, immune system, liver health, nerve health, vitamins and minerals, and women's health across 32 products, sold through pharmacy retail and online channels.
• Hovid Medical Devices Medical devices including 6 blood glucose monitoring devices for diabetes management, sold to pharmacies, healthcare facilities, and consumers.
• Quicklean Disinfectants Antibacterial hand gel and disinfectant solutions for hygiene and sanitization, distributed to pharmacies, healthcare facilities, and retail consumers.
• Hozen Lozenges Herbal lozenges available in 4 variants — Ginger Cinnamon Honey, Lemon Propolis Honey, Mint Menthol Eucalyptus, and Vitamin C Propolis — sold through pharmacy and retail channels.

Quantifiable outcome

• Products marketed to approximately 50 countries globally
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Hovid UK - European OperationscoreStrategic or Co-development PartnerHovid UK serves as the European subsidiary handling product registration, distribution, and marketing of Hovid's pharmaceutical portfolio including ethical pharmaceuticals, dietary supplements, and consumer health solutions. The subsidiary ensures regulatory compliance with EU standards and supports contract manufacturing and licensing partnerships across Europe.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Duopharma Biotech Berhad: Malaysian branded generic pharmaceutical manufacturer operating across similar therapeutic categories (cardiovascular, anti-infectives, oncology) with comparable hospital tender exposure and government-linked demand. Both serve the Malaysian NPRA-regulated market and pursue regional export expansion.
• Pharmaniaga Berhad: Largest Malaysian pharmaceutical company by volume, manufacturing generics and supplying government hospitals. Closest direct domestic peer with overlapping product portfolio, similar regulatory environment, and parallel export growth ambitions.
• Strides Pharma Science: Indian generic pharmaceutical company with explicit emerging-market focus (Africa, Southeast Asia) — the same frontier geographies Hovid targets. Comparable product mix in anti-infectives, anti-malarials, and chronic-disease generics.
• KLK OLEO / DavosLife E3: Malaysian palm oil derivative specialist and dedicated tocotrienol producer (DavosLife brand). Direct competitor in the upstream palm-derived tocotrienol ingredient market and a credible alternative supplier to nutraceutical formulators globally.

Broad incumbents

• Sun Pharmaceutical Industries: India's largest generic pharmaceutical company with broad therapeutic coverage across cardiovascular, CNS, respiratory and specialty segments. Competes with Hovid in emerging-market tenders and represents the global benchmark that constrains generic pricing across the categories Hovid serves.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, competing in cardiovascular, CNS, respiratory and specialty categories across virtually every regulated and emerging market. Sets the global price floor that pressures emerging-market generics players like Hovid.
• Apotex Inc. Canadian generic pharmaceutical manufacturer with broad therapeutic coverage and active emerging-market strategy. Comparable scale and product diversity in generics, including cardiovascular and CNS categories where Hovid also competes.
• Viatris (formerly Mylan/Upjohn): Global generics and specialty pharmaceutical company formed by Mylan-Upjohn combination. Competes directly with Hovid in cardiovascular, anti-infectives, and CNS generics across Asia, Middle East, and Africa, with deep distribution relationships.
• Cipla Limited: Major Indian generic manufacturer with strong respiratory, antiretroviral, and consumer healthcare portfolios. Active across Africa, Southeast Asia and the Middle East — geographies that overlap directly with Hovid's export footprint.
• Dr. Reddy's Laboratories: Indian global generics and biosimilars company with strong hospital, oncology, and emerging-market portfolios. Competes with Hovid across multiple categories in Asia, Africa, and Eastern Europe, with stronger specialty and biosimilar franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Hovid
• LinkedInlinkedin.com/company/hovid-bhd
• Instagraminstagram.com/hovid_malaysia

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hovid Berhad